Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR2 |
Variant | L618V |
Impact List | missense |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | FGFR2 L618V (corresponds to L617V in the canonical isoform) lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). L618V has been shown to confer resistance to Fgfr inhibitors in cell culture (PMID: 28034880) and demonstrates increased Fgfr2 kinase activity compared to wild-type in an in vitro assay (PMID: 28166054), and therefore, is predicted to lead to a gain of Fgfr2 protein function. |
Associated Drug Resistance | Y |
Category Variants Paths |
FGFR2 mutant FGFR2 act mut FGFR2 L618V |
Transcript | NM_001144913.1 |
gDNA | chr10:g.121496546A>C |
cDNA | c.1852T>G |
Protein | p.L618V |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_017015925.2 | chr10:g.121485444G>C | c.1852C>G | p.L618V | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121496546A>C | c.1852T>G | p.L618V | RefSeq | GRCh38/hg38 |
NM_022970 | chr10:g.121496546A>C | c.1852T>G | p.L618V | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121496546A>C | c.1852T>G | p.L618V | RefSeq | GRCh38/hg38 |
NM_001144913 | chr10:g.121496546A>C | c.1852T>G | p.L618V | RefSeq | GRCh38/hg38 |
NM_022970.4 | chr10:g.121496546A>C | c.1852T>G | p.L618V | RefSeq | GRCh38/hg38 |
XM_017015925 | chr10:g.121485444G>C | c.1852C>G | p.L618V | RefSeq | GRCh38/hg38 |
NM_022970.3 | chr10:g.121496546A>C | c.1852T>G | p.L618V | RefSeq | GRCh38/hg38 |
XM_017015925.3 | chr10:g.121485444G>C | c.1852C>G | p.L618V | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 fusion FGFR2 L618V | intrahepatic cholangiocarcinoma | resistant | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Truseltiq (infigratinib) treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 L618V were resistant to treatment as demonstrated by cell viability and downstream signaling assays (PMID: 31109923). | 31109923 |
FGFR2 fusion FGFR2 L618V | intrahepatic cholangiocarcinoma | resistant | Zoligratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Debio 1347 treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 L618V were resistant to treatment, as demonstrated by cell viability and downstream signaling assays (PMID: 31109923). | 31109923 |
FGFR2 fusion FGFR2 L618V | intrahepatic cholangiocarcinoma | sensitive | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Lytgobi (futibatinib) treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 L618V were sensitive to treatment as demonstrated by decreased cell viability and decreased activation of downstream signaling (PMID: 31109923). | 31109923 |